<DOC>
	<DOCNO>NCT00190476</DOCNO>
	<brief_summary>To evaluate efficacy docetaxel-cisplatin combination comparison docetaxel alone elderly patient advance non-small-cell lung cancer .</brief_summary>
	<brief_title>Elderly NSCLC/D v DP ( JCOG0207 )</brief_title>
	<detailed_description>The Elderly Lung Cancer Vinorelbine Italian Study demonstrate first evidence utility chemotherapy elderly patient advance non-small-cell lung cancer ( NSCLC ) . In large randomized trial , gemcitabine vinorelbine fail show advantage either agent alone . With current evidence , single agent chemotherapy third-generation drug consider recommend option elderly patient advance NSCLC . A Japanese phase I/II study show activity ( overall response rate 52 % , median survival 12.4 month ) tolerability weekly docetaxel/ cisplatin combination patient old age 75 year . There randomized prospective trial dedicate elderly NSCLC patient evaluate tolerability efficacy platinum-based combination . Comparison : Single-agent weekly docetaxel versus weekly regimen docetaxel-cisplatin combination elderly advance NSCLC .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>1. histologically cytologically proven nonsmallcell lung cancer 2. stage IV , stage III disease ineligible definitive radiotherapy 3 . 70 year old 4 . ECOG PS 01 5 . Ineligible standard platinum ( bolus infusion ) contain combination chemotherapy 6 . No prior chemotherapy ( contain gefitinib ) nonsmall cell lung cancer neoplasms 7 . No prior surgery within 4 week enrollment 8 . No prior radiotherapy primary tumor 9 . No prior radiotherapy metastatic lesion within 2 week enrollment 10 . Adequate organ function 11 . Signed informed consent 1 . Symptomatic brain metastasis 2 . Active another neoplasms 3 . Severe SVC syndrome 4 . Massive pericardial , pleural effusion , ascites 5 . Bone metastasis emergent palliative radiotherapy surgery 6 . Uncontrollable systemic hypertension 7 . Heart failure , Unstable angina , Myocardial infarction within 6 month 8 . Uncontrollable diabetes 9 . Active infection 10 . Interstitial pneumonia/ Pulmonary fibrosis 11 . Hypersensitivity polysorbate 80 12 . Systemic administration corticosteroid</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Elderly</keyword>
	<keyword>advanced</keyword>
	<keyword>non-small-cell lung cancer</keyword>
	<keyword>cisplatin</keyword>
	<keyword>docetaxel</keyword>
	<keyword>weekly</keyword>
	<keyword>combination</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>randomize trial</keyword>
</DOC>